Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support

Gregg A. Olsen, Jon P. Gockerman, Robert C. Bast, Michael Borowitz, William P. Peters

Research output: Contribution to journalArticle

Abstract

Altered immunologic reconstitution is observed in patients treated with high dose chemotherapy consisting of cyclophosphamide, cisplatin, and carmustine, mel- phalan, or etoposide with autologous bone marrow support, and it is similar to that seen in patients treated with high dose chemoradiotherapy and allogeneic bone marrow transplantation. A decrease in the absolute number and percentage of B cell and CD4 antigen-pos- itive cells and an increase in the absolute number and percentage of CD8 and la antigen-positive cells occur along with a decrease in the CD4/CD8 ratio that persists for 6-12 months after high-dose chemotherapy and autologous bone marrow support. These changes have been associated with four serious infectious episodes usually seen only in immunocompromised patients. The above changes were not seen in patients treated with high-dose busulfan, a drug that has relatively specific effects on granulocytes. It is postulated that these alterations result from effects of chemotherapy on the residual lymphocytes or on the environment of repopulating lymphocytes. Functional studies of lymphocyte populations during immunologic reconstitution after standard- dose combination chemotherapy and high-dose chemotherapy with autologous bone marrow support are needed.

Original languageEnglish (US)
Pages (from-to)57-60
Number of pages4
JournalTransplantation
Volume46
Issue number1
DOIs
StatePublished - Jul 1988
Externally publishedYes

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support'. Together they form a unique fingerprint.

  • Cite this